Adjusted EPS Growth and 2026 Guidance
Full-year 2025 adjusted diluted EPS grew 4.4% to a $5.42 base. Management guided 2026 adjusted diluted EPS of $5.56 to $5.72, implying growth of approximately 2.5% to 5.5%, with growth expected to be weighted to the second half of the year.
Significant Shareholder Returns
Returned ~$8.0 billion to shareholders in 2025 (dividends plus share repurchases). Paid $7.0 billion in dividends, raised the dividend by 3.9% (sixtieth increase in 56 years), repurchased >17 million shares for ~$1.0 billion, with ~$1.0 billion remaining under the $2.0 billion repurchase program.
Strong Full-Year Smokeable Profitability
Smokeable products delivered over $11 billion in adjusted OCI for the full year with adjusted OCI margins expanding 1.8 percentage points to 63.4%. Full-year net price realization was robust at 8.4%.
Nicotine Pouch Growth and ON / ON PLUS Progress
Helix delivered ON full-year reported shipments of more than 177 million cans (≈+11% year over year) and Q4 reported shipments of >44 million cans. ON retail share was 7.7% in Q4 and 8.2% for the full year. FDA granted marketing orders for ON PLUS Mint, Wintergreen, and Tobacco (6 mg and 9 mg); shipments resumed in FL, NC and TX and a national rollout is planned in H1 2026. Management expects Helix to remain profitable in 2026.
International Modern Oral Expansion
Expanded international footprint for Fumi and ON PLUS across e-commerce and targeted retail: Fumi reached ~40,000 retail locations in seven markets and added three line extensions (12 unique flavors total), producing encouraging early performance and consumer insights for future product development.
Industry Smoke-Free Momentum & Regulatory Steps
Total nicotine industry equivalized volumes increased for the third consecutive year and are estimated to have grown ~2% CAGR over the past five years. Smoke-free alternatives are estimated to represent >50% of the total nicotine space (up 5 percentage points from prior year). E-vapor category grew ~30% in 2025. Regulatory progress includes legislation requiring the FDA to allocate at least $200 million of tobacco user fees to enforcement activities and early signs tariffs/enforcement beginning to moderate illicit supply.
Balance Sheet Strength and ABI Income
Total debt to EBITDA was ~2.0x at year-end (in line with target). ABI adjusted equity earnings were $161 million in Q4 (up ~1.3% year over year).
Import/Export Investment with Rapid Payback Potential
Planned CapEx for 2026 elevated to support import-export (duty drawback) and contract manufacturing capabilities (guidance range mentioned $300M–$375M). Management indicated the return on import-export investments is strong with payback under one year and the investments support long-term manufacturing flexibility.